Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.55 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.47 |
| ▸ | CCR4 | P51679 | 3/20 | 0.45 |
| ▸ | EDNRB | P24530 | 2/20 | 0.42 |
| ▸ | EDNRA | P25101 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1830382 | 0.87 | HSD11B1 (0.52) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL1382252 | 0.80 | HSD11B1 (0.62) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL3929016 | 0.79 | HSD11B1 (0.58) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL1380007 | 0.79 | HSD11B1 (0.63) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL1379502 | 0.78 | HSD11B1 (0.59) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL1381363 | 0.78 | HSD11B1 (0.59) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL1378890 | 0.78 | HSD11B1 (0.59) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL1379109 | 0.78 | HSD11B1 (0.69) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL3923837 | 0.78 | HSD11B1 (0.53) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL1830383 | 0.76 | HSD11B1 (0.53) | HSD11B1SLC40A1CCR4EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4809339-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| EP-1763517-B1 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-05-11 | — | — | EP | claimed |
| CN-1972918-B | Pyrimidine derivatives | HOFFMANN LA ROCHE | 2010-10-13 | — | — | CN | claimed |
| US-7507733-B2 | 11b-HSD1 inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | claimed |
| CN-1972918-A | Pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2007-05-30 | — | — | CN | claimed |
| EP-1763517-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-21 | — | — | EP | claimed |
| WO-2006000371-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | claimed |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | US | claimed |
| EP-1763517-B1 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-05-11 | — | — | EP | disclosed |
| US-7507733-B2 | 11b-HSD1 inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1763517-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006000371-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885SLC40A1 2849/4885CCR4 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.